Latest Stories from Cancer

Genzyme to Present New Long-Term Data on Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) at AAN

2015-04-13T06:05:42-07:00

– 30 Presentations Planned On Marketed Products and New Data from Company’s MS Pipeline –

Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2015 Financial Results on April 30, 2015

2015-04-13T06:01:32-07:00

UK’s Aintree University Hospital Joins CEL-SCI’s Phase III Head and Neck Cancer Trial

2015-04-13T05:38:08-07:00

Cologuard® Receives Coverage by Several Commercial Health Plans in Q1 2015

2015-04-13T05:05:59-07:00

Exact Sciences announces expanded patient access to Cologuard as a result of several insurers now covering the test. Cologuard is now covered for more than 90 million lives across the U.S.

Paolo Paoletti, M.D., Named To FORMA Therapeutics Board of Directors

2015-04-13T05:04:08-07:00

FORMA appointed Paolo Paoletti, M.D., to its Board of Directors. He will also lead FORMA's Research & Development Committee as its chairperson. Dr. Paoletti was previously President of GSK Oncology.

Cerulean Announces Publication Showing CRLX101 Targets Breast Cancer Stem Cells and Impedes Resistance to Anti-angiogenic Therapy in Preclinical Models

2015-04-13T04:10:09-07:00

Cerulean today announced the publication of a manuscript in Breast Cancer Research and Treatment, describing preclinical data that demonstrate CRLX101 targets breast cancer stem cells.

Blend Therapeutics Appoints Drew Fromkin as President and Chief Executive Officer

2015-04-13T04:01:59-07:00

Company to Accelerate Development of Cancer Product Pipeline, with Filing of IND for Lead Product Candidate in Q2 2015

IOmet Pharma Demonstrates Superior in Vivo PK/PD Properties in Pre-Clinical IDO1, TDO and Dual IDO1/TDO Cancer Immunotherapy Programs

2015-04-12T22:00:09-07:00

Data to Be Presented April 22 at American Association for Cancer Research 2015 Annual Meeting

Cerulean Closes Public Offering of Common Stock

2015-04-10T06:31:08-07:00

Underwriters fully exercise option to purchase additional shares

Dicerna Presents New β-catenin Data from Multiple Tumor Models at the 2015 RNA & Oligonucleotide Therapeutics Meeting at Cold Spring Harbor Laboratory

2015-04-10T05:02:03-07:00

Data Show Robust Silencing of CTNNB1 Gene in Patient-Derived Xenograft and Other Cancer Models Using RNAi

New Preclinical Data on Tumor Treating Fields to be presented at the American Association for Cancer Research Annual Meeting 2015

2015-04-10T05:01:22-07:00

New Preclinical Data on Tumor Treating Fields to be presented at the American Association for Cancer Research Annual Meeting 2015

Exelixis to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015

2015-04-09T14:05:21-07:00

- Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m. PDT -

Rosetta Genomics to Acquire PersonalizeDx

2015-04-09T09:16:02-07:00

Creates a broader commercial footprint and expanded product offering in oncology diagnostics with numerous near-term product launches to accelerate revenue growth Enhances Rosetta Genomics’ leadership as a provider of proprietary and differentiated content in the personalized medicine arena Rosetta Genomics expects annualized pro forma 2015 revenues of $10 million to $12 million, and 2016 revenues to exceed $18 million

MEDIAN Announces the Award of New Medical Image Interpretation and Management Projects for Clinical Trials for a Total of €2.76M

2015-04-09T09:00:15-07:00

Award* of three Phase II projects sponsored by two major American biotech companies specializing in oncology

Helomics™ to Present at the Personalized Medicine World Conference in Oxford, England

2015-04-09T07:02:02-07:00

Helomics’ to Present an Overview of its Personalized Comprehensive Tumor Profiling Platform